Evolus, Inc.
https://www.evolus.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Evolus, Inc.
Korea Q2 Roundup: In-House Drugs, Exports Help Hanmi, Daewoong, Boryung
Among the strong performers, Hanmi benefitted from growth for in-house-developed metabolic disease drugs and China cold syrup sales and Daewoong was boosted by exports of botulinum toxin, while Boryung reported record quarterly sales helped by its flagship antihypertensive.
Finance Watch: Amylyx, CinCor And Vigil Ready The First Biopharma IPOs Of 2022
Public Company Edition: Mergers with special purpose acquisition corporations also continue to take companies public, with three new SPAC offerings in late 2021. Also, Xeris raised $30m in a private placement of stock to support its recently approved drug and Sirnaomics went public in Hong Kong.
Finance Watch: Five More Small IPOs Squeeze Through The US Window
Public Company Edition: Genenta, Cingulate, ImmixBio, Bionomics and NeuroSense launched initial public offerings, grossing just $118m between them. But Amylyx, with a recently filed ALS drug, has filed to raise up to $100m. In follow-on offerings, Legend took advantage of ASH goodwill to raise $300m.
Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
Company Information
- Industry
- Pharmaceuticals
- Services
-
Pharmaceuticals
- OTC, Consumer
- Other Names / Subsidiaries
-
- ALPHAEON Corporation
- AEON Biopharma, Inc.
- SCH-AEON, LLC
- Strathspey Crown Holdings, LLC
- Strathspey Crown Holdings Group, LLC